Thyreogen®
The biologically active food supplement THYREOGEN® is a complex of low molecular weight peptides
with a molecular weight of up to 5000 Da, obtained from the thyroid gland of young animals - calves
not older than 12 months of age or pigs. The isolated peptides have a tissue-specific effect on thyroid
cells, restoring metabolism and normalizing their functional activity.
THYREOGEN® is produced in tablets or capsules containing 10 mg of active peptides.
THYREOGEN® was administered to patients orally 10-15 minutes before meals, 1-2 capsules 2 times
a day for 20 days, depending on the severity of the pathological process.
Clinical trials of THYREOGEN® were carried out at the Medical Center of the St. Petersburg Institute
of Bioregulation and Gerontology, SZO RAMS, in patients with primary hypothyroidism in the period
from November 2005 to January 2006.
Primary hypothyroidism is one of the age-related disorders of the thyroid gland. In the pathogenesis
of primary hypothyroidism, a change in the gland tissue or inhibition of the synthesis of thyroid hor-
mones due to infectious diseases, trauma, or spontaneous destruction of the thyroid gland comes to
the fore (3, 4).
Drug treatment of primary hypothyroidism includes the use of the following drugs (1, 2):
- Thyroid hormones - thyroidin, thyroxine, triiodothyronine;
- Vitamins B6, B12;
- etc.
CLINICAL CHARACTERISTICS OF PATIENTS
The study involved 25 patients with primary hypothyroidism, including 11 men and 14 women aged
56 to 67 years. The control group consisted of 19 patients, including 7 men and 12 women. Patients
in both groups complained of rapid fatigue, drowsiness, memory impairment, frequent headaches, and
dizziness. In most cases, signs of thyroid atrophy were detected by palpation.
All patients previously received symptomatic therapy for the clinical manifestations of this disease.
Patients in the control group were prescribed conventional means. In addition to conventional drugs,
patients of the primary group received THYREOGEN® 1-2 capsules 2 times a day before meals for
20 days.
RESEARCH METHODS
The patients’ complaints were assessed in dynamics, a general clinical examination of blood and urine,
and a biochemical study of blood on the REFLOTRON apparatus (Boehringer Mannheim, Germany)
were carried out. Ultrasound examination of the thyroid gland was performed using an ultrasound
machine (ALOKA, Japan), electrocardiography - using a CARDIOTEST EK-51 apparatus (Hellinge, Ger-
many).
The content of hormones T3 and T4 in blood serum was determined by radioimmunoassay. The ra-
dioactivity of the samples was counted on a Tracor Analytic 1285 counter (USA-Holland).
RESEARCH RESULTS
As a result of the studies, it was found that the use of THYREOGEN® contributed to the improve-
ment of the clinical manifestations of the disease in 78% of cases, and the most significant effect was
observed in persons of the older age group with pronounced signs of thyroid atrophy. While taking
THYREOGEN®, the patients noted increased working capacity, decreased frequency and intensity of
headaches, and decreased pain in the heart region.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.